Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression
Authors
Keywords
Prostate cancer, U2AF1, ARV7, Bicalutamide-resistance, MAPK1
Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 541, Issue -, Pages 56-62
Publisher
Elsevier BV
Online
2021-01-19
DOI
10.1016/j.bbrc.2020.12.111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
- (2020) Changxue Lu et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
- (2020) Mercedes Marín-Aguilera et al. Cells
- The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis
- (2020) Zhize Wang et al. Cancer Cell International
- Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
- (2019) Maria V. Luna Velez et al. ONCOGENE
- The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation
- (2019) Murali Palangat et al. GENES & DEVELOPMENT
- Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
- (2019) Hench et al. Cancers
- Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
- (2019) Hille et al. Cells
- Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth
- (2017) Hao Yang et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Emerging Technologies in Prostate Cancer Radiation Therapy: Improving the Therapeutic Window
- (2017) Matthew C. Biagioli et al. Cancer Control
- A novel pentacyclic triterpenoid, Ilexgenin A, shows reduction of atherosclerosis in apolipoprotein E deficient mice
- (2016) Chang Liu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Prostate cancer
- (2016) Gerhardt Attard et al. LANCET
- Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
- (2015) Cara Lunn Shirai et al. CANCER CELL
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational analysis of splicing machinery genesSF3B1, U2AF1andSRSF2in myelodysplasia and other common tumors
- (2013) Eun Mi Je et al. INTERNATIONAL JOURNAL OF CANCER
- Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
- (2012) F. Thol et al. BLOOD
- Future Directions in Castrate-Resistant Prostate Cancer Therapy
- (2011) Emmanuel S. Antonarakis et al. Clinical Genitourinary Cancer
- Adjuvant medical therapy for prostate cancer
- (2010) Christopher Sumey et al. EXPERT OPINION ON PHARMACOTHERAPY
- Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
- (2010) Rute B. Marques et al. PLoS One
- Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE
- (2009) David Aaronson et al. BJU INTERNATIONAL
- ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
- (2009) Sebastien Cagnol et al. FEBS Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation